Zobrazeno 1 - 10
of 181
pro vyhledávání: '"Niels Andreasen"'
Autor:
Maarten Timmers, Johannes Rolf Streffer, Alberto Russu, Yushin Tominaga, Hiroko Shimizu, Ayako Shiraishi, Kanaka Tatikola, Pascale Smekens, Anne Börjesson-Hanson, Niels Andreasen, Jorge Matias-Guiu, Miquel Baquero, Mercè Boada, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Abstract Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known
Externí odkaz:
https://doaj.org/article/29adc1da679f4c53b4ec494c0c1dcf5e
Autor:
Niels Andreasen, Monica Simeoni, Henrik Ostlund, Pia I Lisjo, Tormod Fladby, Amy E Loercher, Gerard J Byrne, Frances Murray, Paul T Scott-Stevens, Anders Wallin, Yinghua Y Zhang, Lena H Bronge, Henrik Zetterberg, Agneta K Nordberg, Astrid J Yeo, Shahid A Khan, Jan Hilpert, Prafull C Mistry
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0098153 (2015)
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).This was a tw
Externí odkaz:
https://doaj.org/article/69a0e82640104afeae09379b631cf854
Autor:
Mikko Hölttä, Oskar Hansson, Ulf Andreasson, Joakim Hertze, Lennart Minthon, Katarina Nägga, Niels Andreasen, Henrik Zetterberg, Kaj Blennow
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66381 (2013)
The current study evaluated amyloid-β oligomers (Aβo) in cerebrospinal fluid as a clinical biomarker for Alzheimer's disease (AD). We developed a highly sensitive Aβo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detec
Externí odkaz:
https://doaj.org/article/a8c490b12b5b4840a62088fb5e791df1
Autor:
Konstantinos Chiotis, Kina Höglund, Henrik Zetterberg, Agneta Nordberg, Kaj Blennow, Niels Andreasen, Laetitia Lemoine, Claudia Cicognola, Antoine Leuzy, Laure Saint-Aubert, Keqiang Ye
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Purpose Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau181p) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9204da15beb820f449b8413a91100ba7
https://doi.org/10.1007/s00259-018-4242-6
https://doi.org/10.1007/s00259-018-4242-6
Autor:
Maria Bjerke, Erik Portelius, Lennart Minthon, Anders Wallin, Henrik Anckarsäter, Rolf Anckarsäter, Niels Andreasen, Henrik Zetterberg, Ulf Andreasson, Kaj Blennow
Publikováno v:
International Journal of Alzheimer's Disease, Vol 2010 (2010)
Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of β-amyloid (Aβ42). However, a high discrepancy between different centers in measured Aβ42 le
Externí odkaz:
https://doaj.org/article/ce095aa85bec4fbcbfd6b2e11763d2d0
Publikováno v:
International Journal of Alzheimer's Disease, Vol 2010 (2010)
Due to side effects in the form of meningoencephalitis in the interrupted phase II AN1792 trial of active antiamyloid β(Aβ) immunization against Alzheimer's disease (AD), there has been concern that anti-Aβ immunization may cause destructive neuro
Externí odkaz:
https://doaj.org/article/e2acb15293064ab9a688e4a9145a76b1
Autor:
Peder Buchhave, Kaj Blennow, Henrik Zetterberg, Erik Stomrud, Elisabet Londos, Niels Andreasen, Lennart Minthon, Oskar Hansson
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6294 (2009)
BACKGROUND: The CSF biomarkers tau and Abeta42 can identify patients with AD, even during the preclinical stages. However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat
Externí odkaz:
https://doaj.org/article/bcced03af5c344c6b0feea4113bc952a
Autor:
Daniela Bertens, Tobias Hartmann, Christian Mychajliw, Niels Andreasen, Merja Hallikainen, Thomas Leyhe, Epameinondas Lyros, Johannes Schröder, Lutz Frölich, Noel Ellison, Ineke van Rossum, Yawu Liu, Hans Klünemann, Jennifer Kennel, Anneke M.J. van Hees, Gerwin Roks, Mara ten Kate, Klaus Fassbender, Lars-Olof Wahlund, Matthias Riemenschneider, Frederik Barkhof, Stephan Schiekofer, Alina Solomon, Marcus O. W. Grimm, Hilkka Soininen, Aline Klees-Rollmann, Seppo Helisalmi, Lucrezia Hausner, Miia Kivipelto, Stina Lindblom, Kaj Blennow, Johanna Ml Henselmans, Niklas Koehler, Dieter Lütjohann, Christoph Laske, Göran Hagman, Philip Scheltens, Tarja Lappalainen, Suzanne Hendrix, Yvonne Freund-Levi, Maxine Luley, Daniela Ramelli, Pieter Jelle Visser, Robert Schomburg, Teemu Paajanen, Nienke M.E. Scheltens, Ilona Hallikainen
Publikováno v:
The Lancet Neurology, 16(12), 965-975. Lancet Publishing Group
The Lancet. Neurology
Lancet Neurology, 16(12), 965-975. Elsevier Science
Soininen, H, Solomon, A, Visser, P J, Hendrix, S B, Blennow, K, Kivipelto, M, Hartmann, T & LipiDiDiet clinical study group 2017, ' 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet) : a randomised, double-blind, controlled trial ', The Lancet Neurology, vol. 16, no. 12, pp. 965-975 . https://doi.org/10.1016/S1474-4422(17)30332-0
The Lancet. Neurology
Lancet Neurology, 16(12), 965-975. Elsevier Science
Soininen, H, Solomon, A, Visser, P J, Hendrix, S B, Blennow, K, Kivipelto, M, Hartmann, T & LipiDiDiet clinical study group 2017, ' 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet) : a randomised, double-blind, controlled trial ', The Lancet Neurology, vol. 16, no. 12, pp. 965-975 . https://doi.org/10.1016/S1474-4422(17)30332-0
Background Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f7f291b99a0117afc9dbe3f8653046
https://doi.org/10.1016/s1474-4422(17)30332-0
https://doi.org/10.1016/s1474-4422(17)30332-0
Autor:
Jaren W. Landen, Niels Andreasen, Carol Cronenberger, Henrik Östlund, Martin M. Bednar, Anne Börjesson-Hanson, Pamela F. Schwartz, Catherine Sattler, Brendon Binneman
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05e9a2f46f21ad971447eaf9632b73e
http://europepmc.org/articles/PMC5651442
http://europepmc.org/articles/PMC5651442
Autor:
Pascale Smekens, Niels Andreasen, Mercè Boada, Yushin Tominaga, Luc Van Nueten, Alberto Russu, Jorge Matías-Guiu, Miquel Baquero, Sebastiaan Engelborghs, Ina Tesseur, Johannes Streffer, Ayako Shiraishi, Kanaka Tatikola, Hiroko Shimizu, Luc Tritsmans, Maarten Timmers, Anne Börjesson-Hanson
Publikováno v:
Alzheimers Research & Therapy
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Alzheimer's research & therapy
Alzheimer's Research & Therapy
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Alzheimer's research & therapy
Alzheimer's Research & Therapy
Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known as JNJ-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a6297d9eaeedbe80ecf85135b8bd35
https://doi.org/10.1186/s13195-018-0415-6
https://doi.org/10.1186/s13195-018-0415-6
